TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer.

Autor: Tan, Gongxun¹ (AUTHOR), Jin, Bingquan² (AUTHOR), Qian, Xiaoqin^3,4 (AUTHOR), Wang, Yuguo⁵ (AUTHOR), Zhang, Guoliang⁶ (AUTHOR), Agyekum, Enock Adjei¹ (AUTHOR), Wang, Feng⁷ (AUTHOR), Shi, Liang⁷ (AUTHOR), Zhang, Yue² (AUTHOR), Mao, Zhenwei⁸ (AUTHOR), Shi, Chunhe⁹ (AUTHOR), Xu, Ying¹⁰ (AUTHOR), Li, Xiuying¹⁰ (AUTHOR), Zhang, Lele⁷ (AUTHOR) smilesmilezhang@163.com, Li, Shaohua⁷ (AUTHOR) shli2013@163.com

Publikováno v: Scientific Reports. 10/10/2024, Vol. 14 Issue 1, p1-11. 11p.